Anavex Life Sciences Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2016 - 2020
Period Ending	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021	2016 - 2020
Net Income	-46.38	-43	-47.51	-47.98	-37.91	Upgrade
Stock-Based Compensation	11.55	9.44	16.37	18.38	8.23	Upgrade
Other Operating Activities	-	-	0.85	-	-	Upgrade
Change in Accounts Payable	-5.38	5.31	0.5	-0.91	0.75	Upgrade
Change in Unearned Revenue	-0.04	-0.08	0.47	-	0.44	Upgrade
Change in Other Net Operating Assets	1.2	-2.48	1.54	6.28	-1.9	Upgrade
Operating Cash Flow	-39.04	-30.81	-27.79	-24.24	-30.38	Upgrade
Issuance of Common Stock	12.14	11.98	29.65	22	158.79	Upgrade
Repurchase of Common Stock	-2.71	-	-	-	-	Upgrade
Other Financing Activities	-	-	-	-0.71	-5.55	Upgrade
Financing Cash Flow	9.43	11.98	29.65	21.29	153.24	Upgrade
Net Cash Flow	-29.61	-18.84	1.87	-2.95	122.86	Upgrade
Cash Income Tax Paid	0.13	0.3	0.14	0.33	0.14	Upgrade
Levered Free Cash Flow	-24.39	-19.43	-14.28	-6.03	-15.9	Upgrade
Unlevered Free Cash Flow	-24.39	-19.43	-14.28	-6.03	-15.9	Upgrade
Change in Working Capital	-4.22	2.75	2.51	5.36	-0.71	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.